Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for advanced follicular lymphoma increases median time to progression by 17 months. A US societal cost-effectiveness of R-CVP versus CVP is estimated for a representative 50-year-old patient. Progression-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Hornberger, John, Reyes, Carolina, Lubeck, Deborah, Valente, Nancy
Formato: Texto
Lenguaje:English
Publicado: Informa Healthcare 2008
Materias:
Original Article: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430747/
https://www.ncbi.nlm.nih.gov/pubmed/18231908
http://dx.doi.org/10.1080/10428190701769665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430747/
https://www.ncbi.nlm.nih.gov/pubmed/18231908
http://dx.doi.org/10.1080/10428190701769665

Ejemplares similares